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Abstract
In the present study, in vitro antifungal activities of five antipsychotic drugs (i.e., chlorpro-
mazine hydrochloride, CPZ; trifluoperazine hydrochloride, TPZ; amantadine hydrochlo-
ride; R-(-)-deprenyl hydrochloride, and valproic acid sodium salt) and five conventional
antifungal drugs (i.e., amphotericin B, AMB; caspofungin, CSP; itraconazole; terbinafine,
TRB and voriconazole, VRC) were investigated in broth microdilution tests against four
clinical and five environmental Scedosporium and Pseudallescheria isolates. When used
alone, phenothiazines CPZ and TPZ exerted remarkable antifungal effects. Thus, their in
vitro combinations with AMB, CSP, VRC, and TRB were also examined against the clinical
isolates. In combination with antifungal agents, CPZ was able to act synergistically with
AMB and TRB in cases of one and two isolates, respectively. In all other cases, indifferent
interactions were revealed. Antagonism was not observed between the tested agents.
These combinations may establish a more effective and less toxic therapy after further
in vitro and in vivo studies for Scedosporium and Pseudallescheria infections.
Key words: Scedosporium spp., Pseudallescheria spp., antipsychotic drugs, drug interactions.
Introduction
Members of the genus Scedosporium (teleomorph: Pseu-
dallescheria) are associated with a wide spectrum of hu-
man infections, including trauma-associated, localized dis-
eases (e.g., mycetoma, corneal-, soft tissue- and bone in-
fections) in otherwise healthy people; pulmonary infec-
tions in patients with predisposing pulmonary disorders
(such as cystic fibrosis or pneumonia) and systemic inva-
sive diseases in immunocompromised patients or in near-
drowning victims [1–3]. Systemic infections are more se-
vere and have a tendency for dissemination and central ner-
vous system (CNS) involvement, which is commonly fatal
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Table 1. Overview of the tested non-antifungal agents: mode of action, traditional application, achievable plasma/brain levels
(μg/ml), secondary antifungal activity.
Achievable level (μg/ml) in
Drug Mode of action
Traditional
application plasma brain
Antifungal
activity
Antifungal
mechanism References
Amantadine NMDA receptor
antagonist
Influenza, Multiple
sclerosis,
Parkinson’s disease
– ∼80 Mucorales spp.
Aspergillus spp.
– [15–19]
Phenothiazines:
Clorpromazine,
Trifluoperazine
Postsynaptic
dopaminerg receptor
inhibitor
Schizophrenia 0.5–1 50–100 Candida spp.
Mucorales spp.
Aspergillus spp.
Scedosporium
spp.
Inhibitor of
calmodulin/
Membrane
modifier/ DNA
intercalator
[20–27]
Selegiline
(/R-deprenyl)
Dose-dependent
inhibitor of monoamine
oxidase type A and B
Depression
Parkinson’s disease
∼ 2–6 · 10−3 – Mucorales spp.
Aspergillus spp.
– [17, 28, 29]
Valproic acid Inhibitor of the
arachidonic acid -
arachidonoyl-CoA
conversion
Bipolar disorder – ∼140–210 Mucorales spp.
Aspergillus spp.
– [17, 30, 31]
without treatment [4,5]. The clinical presentations of Sce-
dosporium/Pseudallescheria infections are similar to those
of aspergillosis, thus scedosporiosis can be mistakenly
treated with the generally accepted antifungals for As-
pergillus spp. [6]. This may have severe consequences be-
cause Scedosporium spp. are generally less susceptible to
the commonly used antifungal agents than Aspergillus spp.
[7] When facing with CNS infections the spectrum of el-
igible antifungal agents is still narrow; the most com-
mon approach is an aggressive surgical treatment and/or
a high dosage of AMB (often combined with azole com-
pounds), which penetrates across the blood-brain barrier
(BBB) poorly and may cause serious adverse effects [8–11].
Moreover, Scedosporium/Pseudallescheria species typically
respond poorly to AMBwith aminimum inhibitory concen-
tration (MIC) range of 2–32μg/ml [7,12,13]. Echinocan-
dins proved to be active against Scedosporium spp. [2];
however, they have poor ability to cross the BBB [2,14]. For
these reasons, it is especially challenging to find the appro-
priate therapeutic agents to treat these brain infections and
there is an urgent need for new, safely applicable antifungal
strategies against Scedosporium and Pseudallescheria spp.
An alternative way to cure these types of infections is the
use of non-antifungal drugs with secondary antifungal ac-
tivity, as monotherapeutic agents or in combination with
conventional antifungal drugs. Thus, instead of developing
novel antifungal agents, we could save the time and the
costs of drug design and clinical trials. According to previ-
ous studies, there are a number of medications, which are
originally used to treat mental illnesses (e.g., selegiline for
depression) or degenerative CNS disorders (e.g., amanta-
dine for Parkinson’s disease) but may also have antifungal
activity (Table 1). These antipsychotic drugs can easily pen-
etrate the BBB and accumulate in the CNS [20,21]. Thus,
they represent promising, novel agents in the treatment of
cerebral fungal diseases.
The aim of the present work was to investigate the in
vitro antifungal activities of five non-antifungal drugs and
five traditional antifungal agents against Scedosporium spp.
either alone or in combination with each other.
Materials and methods
Fungal strains and culture conditions
Nine Scedosporium and Pseudallescheria isolates obtained
fromCBS (Centraalbureau voor Schimmelcultures, Utrecht,
The Netherlands) were involved in this study. The iso-
lates derived from a variety of environmental and clini-
cal sources (i.e., dung, human lung, sputum, soil, sewage,
and wound exudate) from different parts of the world
(Table 2). The strains were maintained on malt extract
slants (MEA, Biolab, Hungary) at 4◦C. Susceptibility tests
were performed in RPMI 1640 medium (Sigma-Aldrich,
USA) supplemented with 0.3 g/l L-glutamine and buffered
to pH 7.0 with 0.165M 4-morpholinopropanesulfonic acid
(Sigma-Aldrich, USA).
Antifungal susceptibility tests
The following five antipsychotic drugs were involved in
this study: chlorpromazine hydrochloride (CPZ), trifluop-
erazine hydrochloride (TPZ), amantadine hydrochloride
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(AMD), R-(-)-deprenyl hydrochloride (RDEP) and valproic
acid sodium salt (NaVAP) (Sigma-Aldrich, USA). All drugs
were dissolved in 96% ethanol to prepare stock solutions
(10.24 mg/ml). From the stocks, dilutions were prepared
in RPMI 1640 medium. Final drug concentrations ranged
from 64 to 1024μg/ml for AMD, NaVAP, RDEP and from
4 to 64μg/ml for CPZ and TPZ. The tested conventional
antifungal agents, such as amphotericin B (AMB, Medispec
Pharmaceuticals Pvt. Ltd., India), caspofungin (CSP, Sigma-
Aldrich, USA), itraconazole (ITC, Sigma-Aldrich, USA),
terbinafine (TRB, Sigma-Aldrich, USA) and voriconazole
(VRC, Pfizer PGM, France) were provided by the manufac-
turers as standard powders. The typical solvent of antipsy-
chotic drugs is ethanol; to avoid the possible bias arising
from the different mixtures of solvents, stock solutions (at
5 mg/ml) of antifungal drugs were also prepared in ethanol.
Further dilutions were prepared in RPMI 1640 medium in a
final concentration range of 1–512μg/ml for each antifun-
gal drug. The possibility of incomplete solubilisation of the
drugs (causing higher MIC readings) was ruled out by using
Aspergillus flavus ATCC 204304 as a reference strain.
The in vitro MIC and minimum effective concentration
(MEC) values were determined in a 96-well flat-bottom
microtiter plate bioassay based on the slightly modified
instructions of the Clinical and Laboratory Standards In-
stitute M38-A2 broth microdilution method, in triplicates
[32]. The tested isolates sporulated poorly after 7 days;
hence, in order to get the sufficient amount of conidia, the
CLSI recommended incubation time was extended by an-
other week on MEA slants at 30◦C. Conidia were diluted
in RPMI 1640 adjusting the concentration to 105 coni-
dia/ml. The plates were incubated at 37◦C for 72 h; then the
absorbance (OD620) was measured with a microtiter plate
reader (SPECTROstar Nano, Germany) in well-scanning
mode. The absorbance of the untreated control cultures
were referred to 100% growth in each case. MIC was de-
fined as the lowest antifungal concentration, which was
required for the total growth inhibition of a certain iso-
late. MEC was defined as the lowest concentration of CSP,
which led to abnormally branched, compact hyphal forms.
Interaction tests
Drug interactions between phenothiazines (CPZ and TPZ)
and four conventional antifungals (AMB, CSP, TRB, and
VRC) were investigated using the checkerboard microdi-
lution method [33]. To define the type of interaction be-
tween two compounds, the fractional inhibitory concen-
tration index (FICI) was used [34]. Synergism was defined
as FICI≤0.5, indifference as 0.5<FICI≤4 and antagonism
was defined when FICI>4 [35]. The final CPZ and TPZ
concentrations ranged from 4 to 64μg/ml. The final AMB
concentrations were between 0.125 and 128μg/ml and the
 by guest on N
ovem
ber 17, 2015
http://m
m
y.oxfordjournals.org/
D
ow
nloaded from
 
Homa et al. 893
Table 3. Results of the combination tests of phenothiazines and conventional antifungal drugs against clinical Scedosporium
and Pseudallescheria isolates based on the fractional inhibitory concentration indexes (FICI).
FICIs/ Interaction betweenb
Strain numbera Species CPZ-AMB CPZ-CSP CPZ-TRB CPZ-VRC TPZ-AMB TPZ-CSP TPZ-TRB TPZ-VRC
CBS 136046 S. aurantiacum 0.80/NIc 0.75/NI 0.50/S 1.25/NI 3.00/NI 1.25/NI 2.00/NI 2.00/NI
CBS 116910 S. aurantiacum 1.30/Sc 1.50/NI 0.50/S 1.25/NI 1.30/NI 2.00/NI 2.50/NI 4.00/NI
CBS 120157 P. boydii 0.40/NI 1.50/NI 0.75/NI 2.50/NI 2.30/NI 2.25/NI 3.00/NI 4.00/NI
CBS 117432 P. boydii 0.80/NI 1.25/NI 2.25/NI 2.00/NI 1.00/NI 0.75/NI 1.25/NI 1.50/NI
aCBS, Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.
bAMB, amphotericin B; CPZ, chlorpromazine hydrochloride; CSP, caspofungin; TPZ, trifluoperazine hydrochloride; TRB, terbinafine; VRC, voriconazole.
cNI, no interaction (0.5<FICI≤4); S, synergism (FICI≤0.5).
CSP, TRB and VRC concentrations were between 0.125
and 64μg/ml. Three replicates were performed.
Results
Antifungal susceptibility tests
Susceptibility of Scedosporium and Pseudallescheria iso-
lates to the tested antipsychotic drugs and conventional an-
tifungals are summarized in Table 2. Among antipsychotic
drugs, CPZ and TPZ showed the lowestMICs: 16–32μg/ml
and 8–32μg/ml, respectively. Contrarily, AMD, NaVAP,
and RDEP, with a few exceptions, displayed generally
high MIC values (≥1024μg/ml). Antifungal agents demon-
strated similar antifungal activity against all the tested iso-
lates with high MICs ranged between 8–128μg/ml, ex-
cept VRC, which had a relatively lower MIC range of
8–32μg/ml. The mean MECs of CSP were in a range of
<1.0–16.0μg/ml.
Interaction tests
Compared to the single use, the MIC values of all investi-
gated agents decreased or remained the same in the com-
bination tests (Table 3). To interpret the interaction be-
tween phenothiazines and antifungals, FICIs were calcu-
lated. Based on these values, in most cases no interactions
were revealed between the tested compounds (FICI range:
0.6–4) and antagonism was not detected at all. CPZ was
able to act synergistically in combination with AMB (FICI:
0.4) and TRB (FICI: 0.5).
Discussion
Among antipsychotics, antifungal activities of phenoth-
iazines are the most investigated. Despite their low achiev-
able plasma concentration (0.5–1μg/ml) [20], they have
a great potential to treat patients with locally invasive
fungal infections. Phenothiazines can accumulate in tis-
sues, and their final level in the brain may be a seventy
times higher than their plasma level [20,21]. The moder-
ate in vitro antifungal effect of phenothiazines was previ-
ously described against different fungal pathogens: Can-
dida, Aspergillus, Mucorales and Scedosporium species
[17,20,22,23,25]. The reported MICs of Scedosporium iso-
lates in these experiments ranged from 16 to 128μg/ml.
Our results were comparable to these previously reported
in vitro activities: MICs of CPZ and TPZ were found be-
tween 16–32μg/ml and 8–32μg/ml, respectively (Table 2).
It is noteworthy that these concentrations are in the reach-
able range in the CNS [20,21]. Afeltra et al. [20] reported
that TPZ was more effective against the tested yeasts and
moulds than CPZ: the mean MICs of TPZ were between
21.3 and 38.4μg/ml, while CPZ mean MICs were in the
range of 38.9–53.6μg/ml. In the present study, we also ob-
served that Scedosporium spp. were more sensitive to TPZ
than CPZ, as the mean MICs were 18.6 and 26.6μg/ml,
respectively.
The antifungal potential of the other three non-
antifungals (AMD, NaVAP and RDEP) was recently in-
vestigated by our group [17] and a slight antifungal effect
(MIC≥512μg/ml) was observed against Mucorales moulds
and Aspergillus spp. With only one exception, we also
found similarly high MICs (≥256μg/ml) against Scedospo-
rium/Pseudallescheria spp.; S. aurantiacum CBS 116910
proved to be more sensitive to NaVAP than the other tested
isolates (MIC<64μg/ml). Apart from the latter case, other
concentrations of NaVAP obtained in this study are un-
reachable in the CNS during the therapy [18,29,30].
Scedosporium spp. reported to be intrinsically resistant
to the majority of the current antifungals: their high in
vitro MIC values seemed to correlate with the poor re-
sponse to clinical therapy [27,36,37]. The previously deter-
minedMICs of AMB, CSP, ITC, TRB and VRCwere highly
variable and were in the ranges of 0.125–>32μg/ml, 0.5–
>16μg/ml, 0.03–>32μg/ml, 1–>32μg/ml, and ≤0.03–
>16μg/ml, respectively [12,36–46]. Compared to these
data, all tested isolates responded poorly to the five
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antifungal agents in the present work. Although our MIC
results were less variable, they were all in a higher range
(8–128μg/ml), and these concentrations cannot be reached
under therapeutical conditions in the CNS [17,47]. How-
ever, in agreement with the report of Wiederhold et al.
[45], MEC values of CSP were at least 4-fold lower than
the MICs.
In vitro combination of antipsychotic drugs and conven-
tional antifungal agents is a less studied field. Previously,
we investigated the in vitro interactions between these two
groups of drugs against Aspergillus spp., Candida spp.
and representatives of the order Mucorales [17,22,23]. The
combinations of phenothiazines and amphotericin B were
able to act both antagonistically and synergistically against
Candida strains [22]. Against Mucoralean fungi, TPZ acted
synergistically, while CPZ acted antagonistically with AMB
[23]. In contrast to these, we did not detect antagonism
between the antifungal and non-antifungal agents against
Scedosporium isolates. In most cases, there were no interac-
tions between the two compounds, but CPZ was able to act
synergistically with both AMB and TRB (Table 3). Wood
et al. [48] also observed synergism between CPZ and AMB
against Candida spp.
In conclusion, these results underline the need of fur-
ther in vitro and in vivo studies to clarify the mode of
action and to prove the possible clinical efficiency of the
discussed non-antifungal drugs against Scedosporium and
Pseudallescheria spp.
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